Ivermectine Pharmaki Generics

Ivermectin, the active ingredient in Ivermectine Pharmaki Generics, is a macrocyclic lactone presented as an oral formulation for systemic use. It is employed to treat a range of parasitic infections in both adult and pediatric patients where indicated. GNH USA supplies Ivermectine Pharmaki Generics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectin acts on a variety of helminthic and ectoparasitic diseases, reducing parasite burden and associated symptoms. - Onchocerciasis: lowers microfilarial load and helps control disease progression. - Strongyloidiasis: eradicates intestinal larvae and prevents disseminated infection. - Lymphatic filariasis: reduces circulating microfilariae, aiding mass‑drug‑administration programs. - Scabies: eliminates Sarcoptes mites, relieving itching and skin lesions. - Pediculosis: kills head lice and nits, stopping infestation spread.

Ivermectin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: transient feeling of light‑headedness. - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, usually self‑limiting. - Abdominal pain: cramping or discomfort. - Pruritus: mild skin itching. - Headache: occasional tension‑type headache.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate care. - Hepatic injury: elevated liver enzymes or jaundice. - Neurologic toxicity: seizures or altered mental status. - Anaphylaxis: rapid onset of allergic reaction. - Vision changes: blurred vision or optic neuritis. - Severe skin rash: extensive erythema or bullae.

Before prescribing ivermectin, clinicians should consider several safety factors. - Assess liver function: evaluate hepatic status prior to initiation. - Screen for Loa loa infection: avoid in patients with high microfilaremia due to risk of severe reactions. - Use with caution in pregnancy: limited safety data, weigh benefits against potential risks. - Monitor for drug interactions: especially with CYP3A4 or P‑gp inhibitors. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ivermectin may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can markedly increase ivermectin plasma concentrations. - P‑glycoprotein inhibitors (e.g., verapamil, quinidine): may raise systemic exposure.

Moderate Interactions (Monitor Closely): - Warfarin: potential enhancement of anticoagulant effect, monitor INR. - Macrolide antibiotics (e.g., erythromycin): may modestly increase ivermectin levels. - Anticonvulsants (e.g., carbamazepine, phenytoin): may reduce ivermectin efficacy by inducing metabolism.